Sexual Desire
Vyleesi® is approved for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide
Peptide Therapy in Pasadena
What Is Bremelanotide?
Bremelanotide, marketed as Vyleesi®, is a synthetic peptide that activates melanocortin receptors involved in sexual desire and neuroendocrine signaling.
FDA-approved use: Vyleesi® is approved for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide may also be prescribed off-label for men experiencing low libido or erectile concerns. These uses are not FDA-approved, and supporting research remains limited.
Why Is Bremelanotide Gaining Attention?
Bremelanotide acts on the brain’s melanocortin system, which is involved in sexual desire and arousal. Research continues to explore its broader neuroendocrine effects.
Melanocortin Signaling
Bremelanotide activates central melanocortin receptors involved in desire and arousal rather than acting directly on blood flow.
Neuroendocrine Pathways
Researchers continue to study its relationship to mood, stress signaling, appetite, and metabolic regulation.
Important: Vyleesi® is not FDA-approved for men, postmenopausal women, or sexual-performance enhancement. Any use outside the approved indication is off-label, requires an individualized medical assessment, and may have limited supporting evidence.
Bremelanotide Therapy at Alpha Hormones® Pasadena
At Alpha Hormones®, we provide personalized consultations to determine whether peptide therapy—including Bremelanotide—aligns with your sexual wellness goals. Our licensed providers review FDA-approved indications, discuss off-label considerations when appropriate, and prioritize safe, medically guided care.
Available delivery methods include:
- Subcutaneous injection – self-administered before anticipated sexual activity.
- Intranasal spray – discussed as an alternative route for systemic absorption
- Oral troche – compounded forms that may also be combined with other sexual wellness medications, such as tadalafil or oxytocin, when clinically appropriate
What to expect: Some individuals report transient effects within hours, while others experience more gradual changes. Commonly reported temporary side effects include mild nausea, flushing, or headache. All potential reactions are reviewed prior to administration. Our Bremelanotide formulations are sourced only from GMP-compliant, licensed pharmacies, ensuring consistency and safety.
Who May Consider Bremelanotide Therapy?
Individuals who explore Bremelanotide therapy at Alpha Hormones® are often those who:
- Experience low sexual desire and want to understand options such as FDA-approved Vyleesi®
- Are open to discussing evidence-based, peptide-driven approaches to intimacy and confidence
- Seek professional, discreet, and medically guided support
Every patient begins with a private consultation to review health history, hormones, and goals. Our providers create an individualized plan focused on safety, education, and empowerment.
Frequently Asked Questions
Yes — Bremelanotide (Vyleesi®) is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. All other uses, including in men, are considered off-label and must be discussed with a licensed medical provider.
It is a melanocortin receptor agonist, meaning it influences neural pathways related to sexual desire and arousal, rather than acting on hormones directly.
Typically as a subcutaneous injection before anticipated intimacy. Some compounding pharmacies may also prepare intranasal or oral formulations for research or wellness contexts.
Some individuals report noticeable changes within hours, but experiences vary. Bremelanotide should be used only under professional guidance.
The most common side effects include temporary nausea, flushing, and mild headache. Most are short-lived and dose-related.
While not FDA-approved for men, Bremelanotide’s mechanism of action is not sex-specific. Some clinicians discuss off-label use for men in select cases, always with informed consent and medical oversight.
In some cases, yes — especially in compounded troche form. Providers may combine Bremelanotide with medications such as tadalafil or oxytocin if clinically appropriate. This should only be done under licensed medical supervision.
Not necessarily. It may not be appropriate for individuals with uncontrolled hypertension, cardiovascular disease, or certain medication interactions. A medical consultation is required.
All formulations are obtained from licensed, GMP-compliant U.S. pharmacies to ensure consistency, purity, and safety.
Testing is often recommended to rule out hormonal or metabolic causes of low libido and to ensure safe use of peptide-based therapies.
Coverage varies. FDA-approved Vyleesi® may be covered under certain plans for eligible women. Compounded or off-label formulations are typically self-pay.
Yes. In most cases, patients can use FSA or HSA funds for medically supervised peptide consultations and peptide prescriptions, as long as they are ordered by a licensed medical provider and documented as part of a treatment plan.
Schedule a Private Consultation
At Alpha Hormones® in Pasadena, we specialize in hormone and peptide-based wellness with an emphasis on individualized care, safety, and transparency.
Interested in Bremelanotide (Vyleesi®)?
Schedule a confidential consultation with one of our licensed medical providers to explore whether this therapy may be an appropriate option for your personal wellness goals.
Disclaimer
Bremelanotide (Vyleesi®) is FDA-approved only for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). All other uses are considered off-label. The information provided is for educational purposes only and is not a substitute for professional medical advice. Individual responses vary, and no outcomes are guaranteed. All treatment decisions should be made in consultation with a licensed healthcare provider following a personalized evaluation.
